NKTR Drug delivery Company Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : NKTR Drug delivery Company

NKTR 55.97

+1.5%

Nov 7 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: tuck who wrote (440)	11/8/2018 3:21:59 AM
From: Miljenko Zuanic	Read Replies (1) of 507

Hard to say what will come out of SITC/ASH (read-out of 3Q cc), most likely CR-% and response durability may be played as factor for ongoing 1L melanoma, as well as RCC? Anyway, bit of the light that all (214) is not dad yet. Refocus on 2L relapse/refractory (PD1/chemo relapse) PDL1+ NCSLC is logical choice (as significant market population that is yet to benefit from any regiment). 20% RR may not be that bad, but I think that FDA would want to see something more in this line???!!! My first Q would be, how many subjects of the PDL1- 2L-NCSLC population were converted into "hot" tumor phenotype?

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next